Видео ютуба по тегу Pembrolizumab

Neoadjuvant Pembrolizumab for Lung Cancer | NEJM
Neoadjuvant Pembrolizumab for Lung Cancer | NEJM
Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC
Dr. Herbst on Long Term Survival With Pembrolizumab in NSCLC
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
ESMO 2020 Highlights on pembrolizumab as 1st line therapy for aUC: The KEYNOTE-361 study
Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
Pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
Pembrolizumab
Pembrolizumab
Antibiotics impact outcomes with pembrolizumab in NSCLC patients
Antibiotics impact outcomes with pembrolizumab in NSCLC patients
Pembrolizumab, Tumor Response, and Survival in Advanced Melanoma
Pembrolizumab, Tumor Response, and Survival in Advanced Melanoma
Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC
Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC
Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer
Dr. Burtness on the Benefit of Pembrolizumab in Head and Neck Cancer
Keynote 671: Perioperative Pembrolizumab for NSCLC - OncTalk Lung 2023
Keynote 671: Perioperative Pembrolizumab for NSCLC - OncTalk Lung 2023
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
Pembrolizumab is safe and effective and substantially increases overall survival in aNSCLC patients
Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer
Endometrial Cancer Health Outcomes: pembrolizumab for patients with MSI-high endometrial cancer
Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM
Adjuvant Pembrolizumab and Survival in Renal-Cell Carcinoma | NEJM
KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC
KEYNOTE-407: pembrolizumab plus chemo improves OS and PFS in NSCLC
KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma
KEYNOTE-716: pembrolizumab for patients with high-risk stage II melanoma
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
KEYNOTE-522: 5-year follow-up of pembrolizumab in triple-negative breast cancer
Pembrolizumab plus docetaxel used to treat patients with mCRPC
Pembrolizumab plus docetaxel used to treat patients with mCRPC